Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Wize Pharma stock price, quote, forecast and news

WIZP
US97751M2070

Price

0.96
Today +/-
+0
Today %
+0 %
P

Wize Pharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Wize Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Wize Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Wize Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Wize Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Wize Pharma Stock Price History

DateWize Pharma Price
4/26/20210.96 undefined
4/23/20210.91 undefined

Wize Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Wize Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Wize Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Wize Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Wize Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Wize Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Wize Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Wize Pharma’s growth potential.

Wize Pharma Revenue, EBIT and net profit per share

DateWize Pharma RevenueWize Pharma EBITWize Pharma Net Income
2024e-9,236.1 TT undefined0 undefined-486.32 M undefined
2023e-9,179.24 TT undefined0 undefined-486.32 M undefined
2022e0 undefined0 undefined0 undefined
2021e0 undefined0 undefined0 undefined
20200 undefined-2.44 M undefined-4.93 M undefined
20190 undefined-3.17 M undefined-3.45 M undefined
20180 undefined-3.63 M undefined-3.28 M undefined
20170 undefined-1.48 M undefined-2.97 M undefined
20160 undefined-631,000 undefined-916,000 undefined
20150 undefined-1.39 M undefined-1.48 M undefined
20140 undefined-1.15 M undefined-1.2 M undefined
20130 undefined-3.27 M undefined-2.84 M undefined
20120 undefined-2.51 M undefined-1.86 M undefined
20110 undefined-350,000 undefined-1.4 M undefined
20100 undefined-10,000 undefined-20,000 undefined
20090 undefined-20,000 undefined0 undefined
20080 undefined-20,000 undefined-30,000 undefined
20070 undefined-10,000 undefined-20,000 undefined
20060 undefined10,000 undefined10,000 undefined

Wize Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2006200720082009201020112012201320142015201620172018201920202021e2022e2023e2024e
00000000000000000-9.18 T-9.24 T
------------------0.62
-------------------
0000000000000000000
000000-2-3-1-10-1-3-3-20000
-------------------
00000-1-1-2-1-10-2-3-3-400-486-486
-------100.00-50.00---50.00-33.33----
0.110.110.110.110.110.360.440.440.440.440.443.445.6510.5216.670000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Wize Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Wize Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (k)PROVISIONS (k)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200620072008200920102011201220132014201520162017201820192020
                             
000003.611.561.60.80.70.540.543.220.733.08
000000000000000
000000000000000
000000000000000
00000033000075218041969
000003.611.891.60.80.70.550.593.41.153.15
00000000100582929
000001.340.400000000
000000000000000
000000000000000
000000000000000
000000000000000
000001.340.400000.010.010.030.03
000004.952.291.60.80.70.550.63.41.183.18
                             
10101010105050101010104101633
0.130.130.130.130.134.574.835.475.495.525.5223.430.2734.4935.11
-0.18-0.2-0.23-0.22-0.25-1.4-3.26-6.1-7.3-8.77-9.69-26.45-30-33.9-39.22
0000000480102-340-47-73-73-73
000000000000000
-0.04-0.06-0.09-0.08-0.113.221.62-0.14-1.69-3.28-4.16-3.10.210.53-4.15
0010101010000002393063690
01020203015020000000022628
003000000000250250250250
0.040.050.040.050.060.1401.492.463.694.463.22.6400.27
000000000000000
0.040.060.10.080.10.30.21.492.463.694.463.693.190.641.14
000000000000000
000000000000000
000001.440.470.010000005.49
000001.440.470.010000005.49
0.040.060.10.080.11.740.671.52.463.694.463.693.190.646.64
000.010-0.014.962.291.360.770.410.30.593.41.182.49
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Wize Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Wize Pharma's financial health and stability.

Assets

Wize Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Wize Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Wize Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Wize Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200620072008200920102011201220132014201520162017201820192020
00000-1-1-2-1-10-2-3-3-4
000000000000000
000000000000000
000000000000000
000001020101012
000000000000000
000000000000000
000000-20000-1-2-2-1
000000000000000
000000000000000
000000000000000
000000000000000
000000000000000
000003000000500
000003000001400
---------------
000000000000000
000003-2000002-20
000000000000000
000000000000000

Wize Pharma stock margins

The Wize Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Wize Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Wize Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Wize Pharma's sales revenue. A higher gross margin percentage indicates that the Wize Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Wize Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Wize Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Wize Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Wize Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Wize Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Wize Pharma Margin History

Wize Pharma Gross marginWize Pharma Profit marginWize Pharma EBIT marginWize Pharma Profit margin
2024e0 %0 %0 %
2023e0 %0 %0 %
2022e0 %0 %0 %
2021e0 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %
20070 %0 %0 %
20060 %0 %0 %

Wize Pharma Stock Sales Revenue, EBIT, Earnings per Share

The Wize Pharma earnings per share therefore indicates how much revenue Wize Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Wize Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Wize Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Wize Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Wize Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Wize Pharma Revenue, EBIT and net profit per share

DateWize Pharma Sales per ShareWize Pharma EBIT per shareWize Pharma Earnings per Share
2024e-18.99 B undefined0 undefined-1 undefined
2023e-18.87 B undefined0 undefined-1 undefined
2022e0 undefined0 undefined0 undefined
2021e0 undefined0 undefined0 undefined
20200 undefined-0.15 undefined-0.3 undefined
20190 undefined-0.3 undefined-0.33 undefined
20180 undefined-0.64 undefined-0.58 undefined
20170 undefined-0.43 undefined-0.86 undefined
20160 undefined-1.45 undefined-2.11 undefined
20150 undefined-3.18 undefined-3.39 undefined
20140 undefined-2.63 undefined-2.75 undefined
20130 undefined-7.43 undefined-6.45 undefined
20120 undefined-5.7 undefined-4.23 undefined
20110 undefined-0.97 undefined-3.89 undefined
20100 undefined-0.09 undefined-0.18 undefined
20090 undefined-0.18 undefined0 undefined
20080 undefined-0.18 undefined-0.27 undefined
20070 undefined-0.09 undefined-0.18 undefined
20060 undefined0.09 undefined0.09 undefined

Wize Pharma business model

Wize Pharma Inc. is a leading biopharmaceutical company specializing in the development and marketing of innovative products for the treatment of eye diseases. The company was founded in 1997 and is headquartered in Herzliya Pituach, Israel. It focuses on the research, development, manufacturing, and marketing of eye disease treatments. The company aims to become a leading brand in the field of eye health and offers high-quality services in eye care. Wize Pharma Inc. operates different divisions, with its main divisions being the development and marketing of eye therapeutics, including LO2A and LO2B. LO2A is an innovative therapy for dry eye, while LO2B is an intraoperative formulation used in glaucoma surgery. The company's products provide effective and sustainable solutions for the treatment of eye diseases. Wize Pharma is one of the most popular companies on Eulerpool.com.

Wize Pharma SWOT Analysis

Strengths

Wize Pharma Inc possesses several strengths that contribute to its competitive advantage in the market. These strengths include:

  • Diverse product portfolio leading to revenue diversification.
  • Strong intellectual property rights and patents providing a barrier to entry for competitors.
  • Experienced and knowledgeable management team with a proven track record.
  • Established distribution channels and partnerships enabling market reach and customer access.
  • Robust research and development capabilities driving innovation and new product development.

Weaknesses

Despite its strengths, Wize Pharma Inc also faces certain weaknesses that might hinder its growth and competitiveness:

  • Reliance on a limited number of key suppliers, leading to potential supply chain disruptions.
  • Highly competitive market with numerous established pharmaceutical companies.
  • Limited financial resources for large-scale marketing and advertising campaigns.
  • Dependence on regulatory approvals and compliance, subject to potential delays and uncertainties.
  • Limited brand recognition compared to more established competitors.

Opportunities

Wize Pharma Inc can capitalize on various opportunities in the market to further expand its business and profitability:

  • Growing global demand for innovative and effective pharmaceutical products.
  • Potential collaborations and strategic partnerships for research and development expansion.
  • Emerging markets with untapped potential for market penetration.
  • Advancements in technology that can enhance drug discovery and development processes.
  • Changing consumer preferences towards natural and organic healthcare solutions.

Threats

Wize Pharma Inc should be aware of potential threats that could negatively impact its business and profitability:

  • Stringent regulations and compliance requirements leading to increased costs and delays.
  • Aggressive competition from both domestic and international pharmaceutical companies.
  • Economic downturns and financial volatility affecting consumer purchasing power.
  • Intellectual property infringements and counterfeit products harming brand reputation.
  • Rapid technological advancements requiring continuous investment in research and development.

Wize Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Wize Pharma historical P/E ratio, EBIT, and P/S ratio.

Wize Pharma shares outstanding

The number of shares was Wize Pharma in 2023 — This indicates how many shares 16.67 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Wize Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Wize Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Wize Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Wize Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Wize Pharma.

Most common questions regarding Wize Pharma

What values and corporate philosophy does Wize Pharma represent?

Wize Pharma Inc is a reputable company that upholds strong values and embodies a comprehensive corporate philosophy. With a steadfast commitment to excellence, Wize Pharma Inc prioritizes integrity, innovation, and accountability. This pharmaceutical company strives to deliver high-quality products and services to meet the ever-evolving needs of their customers. Through a continuous pursuit of knowledge and advancement, Wize Pharma Inc ensures the utmost satisfaction of their stakeholders. By incorporating ethical business practices and promoting transparency, this esteemed company establishes trust and credibility within the industry. Wize Pharma Inc remains dedicated to improving healthcare outcomes and enhancing the overall well-being of individuals worldwide.

In which countries and regions is Wize Pharma primarily present?

Wize Pharma Inc is primarily present in the United States, Israel, and China.

What significant milestones has the company Wize Pharma achieved?

Since its inception, Wize Pharma Inc has achieved several significant milestones. The company successfully developed and gained FDA approval for LO2A, its leading ophthalmic solution for the treatment of Dry Eye Syndrome (DES). In addition, Wize Pharma Inc established distribution agreements in various markets, expanding the global accessibility of LO2A. Furthermore, the company initiated clinical trials to evaluate LO2A's potential in treating other eye-related conditions. These achievements demonstrate Wize Pharma Inc's commitment to developing innovative solutions and expanding its presence in the ophthalmic market.

What is the history and background of the company Wize Pharma?

Wize Pharma Inc, founded in 1997, is a pharmaceutical company specializing in the development and commercialization of ophthalmic medications. Based in Israel, it focuses on innovative treatments for various ocular conditions, including dry eye syndrome. Wize Pharma Inc has a rich background of research and collaboration with renowned medical institutions to enhance its product portfolio. The company is dedicated to providing effective and safe solutions to improve eye health worldwide. With its commitment to research and development, Wize Pharma Inc continues to strive for advancements in ophthalmic therapeutics.

Who are the main competitors of Wize Pharma in the market?

The main competitors of Wize Pharma Inc in the market include pharmaceutical companies such as Pfizer, Novartis, Johnson & Johnson, and Eli Lilly.

In which industries is Wize Pharma primarily active?

Wize Pharma Inc is primarily active in the healthcare industry.

What is the business model of Wize Pharma?

Wize Pharma Inc is a pharmaceutical company that specializes in developing and commercializing ophthalmic medications. Their business model focuses on acquiring and licensing innovative ophthalmic drug products, conducting research and development, and seeking regulatory approvals. Wize Pharma Inc aims to meet the unmet medical needs in ophthalmology by improving existing therapeutic agents or developing new treatments for various eye disorders. Through strategic partnerships and collaborations, they strive to deliver cutting-edge solutions to the ophthalmic community and patients worldwide.

What is the P/E ratio of Wize Pharma 2024?

The Wize Pharma P/E ratio is -0.03.

What is the P/S ratio of Wize Pharma 2024?

The Wize Pharma P/S ratio is -0.

What is the AlleAktien quality score of Wize Pharma?

The AlleAktien quality score for Wize Pharma is 5/10.

What is the revenue of Wize Pharma 2024?

The expected Wize Pharma revenue is -9,236.1 TT USD.

How high is the profit of Wize Pharma 2024?

The expected Wize Pharma profit is -486.32 M USD.

What is the business model of Wize Pharma

Wize Pharma Inc is a company specialized in the development and marketing of medications. It focuses on eye diseases such as cataract, dry eye, and certain corneal diseases. The company is headquartered in Israel and is listed on the Tel Aviv Stock Exchange. Wize Pharma's business model is based on three main aspects: research, development, and marketing. The research department develops new active substances and technologies to find targeted therapeutic solutions for eye diseases. The development department is responsible for manufacturing active substances and medications based on the research results. Finally, marketing is done through the distribution of medications to doctors and pharmacies, as well as collaboration with partner companies. One of Wize Pharma's key products is the medication LO2A. It was specifically developed for the treatment of cataract and is approved in several countries, including Israel, the USA, and Canada. What makes LO2A unique is that it contains a natural substance called lanosterol, which studies have shown can prevent the formation of cataracts in the eyes. Another product in Wize Pharma's portfolio is the medication PLxGuard. It was developed specifically for the treatment of dry eye and contains Omega-3 fatty acids and Vitamin E, among other ingredients. PLxGuard is also approved in some countries and is marketed through the company's own distribution channel and partner companies. Wize Pharma emphasizes high quality and intensive collaboration with doctors and pharmacies in the marketing of its products. Regular training and continuing education are provided to healthcare professionals to keep them informed about the latest developments in the field of ophthalmology, enabling them to recommend the best possible therapy to their patients. Wize Pharma also maintains high quality standards and transparency in its collaboration with partner companies. Overall, Wize Pharma's business model is characterized by high innovation and a clear focus on the needs of patients with eye diseases. With the combination of research, development, and marketing, the company is well-positioned to continue its success and contribute to improving the health and quality of life for people with eye diseases.

What is the Wize Pharma dividend?

Wize Pharma pays a dividend of 0 USD distributed over payouts per year.

How often does Wize Pharma pay dividends?

The dividend cannot currently be calculated for Wize Pharma or the company does not pay out a dividend.

What is the Wize Pharma ISIN?

The ISIN of Wize Pharma is US97751M2070.

What is the Wize Pharma ticker?

The ticker of Wize Pharma is WIZP.

How much dividend does Wize Pharma pay?

Over the past 12 months, Wize Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Wize Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Wize Pharma?

The current dividend yield of Wize Pharma is .

When does Wize Pharma pay dividends?

Wize Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Wize Pharma?

Wize Pharma paid dividends every year for the past 0 years.

What is the dividend of Wize Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Wize Pharma located?

Wize Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Wize Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Wize Pharma from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Wize Pharma pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Wize Pharma in the year 2023?

In the year 2023, Wize Pharma distributed 0 USD as dividends.

In which currency does Wize Pharma pay out the dividend?

The dividends of Wize Pharma are distributed in USD.

All fundamentals about Wize Pharma

Our stock analysis for Wize Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Wize Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.